Inovio Pharmaceuticals

Inovio Pharmaceuticals is facing an investigation by Robbins LLP over allegations of misleading investors about its Inovio Pharmaceuticals===CELLECTRA device's approval. This could negatively impact its stock price and reputation.

Inovio Pharmaceuticals is facing a securities fraud lawsuit due to alleged misleading statements regarding its INO-3107 treatment and CELLECTRA device. The company's stock price fell significantly after delays in FDA submission and the acceptance of a standard review timeline instead of an accelerated one, injuring investors.

Inovio Pharmaceuticals is facing a class action lawsuit due to allegedly misleading statements regarding its CELLECTRA device manufacturing and the prospects of its INO-3107 Biologics License Application. The United States===Food and Drug Administration's decision to accept the BLA on a standard review timeline, rather than accelerated approval, caused a significant drop in Inovio Pharmaceuticals' stock price.

Inovio Pharmaceuticals is facing a class action lawsuit alleging that it made false and misleading statements regarding the manufacturing of its CELLECTRA device and the regulatory prospects of its INO-3107 Biologics License Application. This could lead to significant financial penalties and reputational damage for Inovio Pharmaceuticals.

Inovio Pharmaceuticals is facing a class action lawsuit due to alleged materially false and misleading statements regarding its business, operations, and prospects, particularly concerning the INO-3107 BLA and CELLECTRA device. The lawsuit and the underlying issues have led to significant stock price declines and negative market sentiment.